Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
TLDR
Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
View on PubMed
Absolute Cardiovascular Disease Risk and Shared Decision Making in Primary Care: A Randomized Controlled Trial
TLDR
A simple transactional decision aid based on calculating absolute individual CVD risk and promoting shared decision making in CVD prevention can be disseminated through CME groups and may lead to higher patient satisfaction and involvement and less decisional regret, without negatively affecting global CVDrisk.
View on Publisher
The Ariadne principles: how to handle multimorbidity in primary care consultations
TLDR
To provide orientation in decision making in multimorbidity during primary care consultations, guiding principles are developed and named after the Greek mythological figure Ariadne and recognized and appreciated as important by family physicians and primary care researchers.
View on Springer
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review.
View on PubMed
Internal consistency of the readiness for interprofessional learning scale in German health care students and professionals
TLDR
The overall RIPLS-D scale is reliable, several subscales showed low values and should be used with caution to measure readiness for interprofessional learning in the German health care context, and the sub-scale “roles and responsibilities” was problematic.
View on Springer
Predictors of Health-Related Quality of Life in Patients at Risk for Cardiovascular Disease in European Primary Care
TLDR
In patients at risk for CVD, good medication adherence, regular physical activity, controlling of biomedical risk factor levels and patient-centered practice organization have been shown to be positively correlated to HRQoL and should therefore be targeted in interventions not only to reduce morbidity but also to sustain or even to ameliorate HRZoL.
View PDF
Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival.
TLDR
Young patients, primary with non-metastatic disease and HER2+ tumors, have a high risk to develop CM in MBC, and survival of patients developing CM in the course of MBC is impaired compared with patients without CM.
View on PubMed
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
TLDR
If the hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life.
View on Springer
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
TLDR
Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information.
View on Springer
A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial
TLDR
The COMBATAC trial is designed to evaluate the feasibility and efficacy of the combined multidisciplinary treatment regimen consisting of perioperative systemic combination chemotherapy plus cetuximab and CRS plus bidirectional HIPEC with intraperitoneal oxaliplatin.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License